Reuters logo
BRIEF-Omeros announces positive data from OMS721 phase 2 clinical trial in renal diseases
2016年10月17日 / 中午11点32分 / 1 年前

BRIEF-Omeros announces positive data from OMS721 phase 2 clinical trial in renal diseases

Oct 17 (Reuters) - Omeros Corp

* Omeros announces positive data from OMS721 Phase 2 clinical trial in renal diseases

* Statistical significance was achieved on key endpoints of improvement in renal function

* Consistent with other clinical trials with OMS721, no significant safety concerns have been observed

* Plans to advance OMS721 rapidly through its IGA nephropathy development program to support both U.S. and international marketing authorizations

* Additional data from Omeros’ OMS721 program are expected later this year Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below